Position in NVS
as of Jun 30, 2026
· filed Jul 20, 2026
Position Value
$34,478
+$873 QoQ
Shares Held
220
0.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#1,459
of 1,603 holders
Holding Since
Mar 2025
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Nexus Investment Management ULC holds $61,054,403 across 9 Drug Manufacturers - General names. NVS ranks #9 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | GILD |
Gilead Sciences, Inc.
|
251,016 | $31,713,361 | |
| 2 | PFE |
Pfizer Inc
|
1,023,770 | $24,652,381 | |
| 3 | JNJ |
Johnson & Johnson
|
8,381 | $2,128,522 | |
| 4 | LLY |
ELI LILLY & Co
|
769 | $922,361 | |
| 5 | ABBV |
AbbVie Inc.
|
3,456 | $869,667 | |
| 6 | MRK |
Merck & Co., Inc.
|
3,735 | $479,947 | |
| 7 | BIIB |
Biogen Inc.
|
920 | $198,775 | |
| 8 | BMY |
Bristol Myers Squibb Co
|
953 | $54,911 |
All Filings in NVS
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $34,478 | 220 | Shares | Sole | 2026-07-20 | |
| 2026-03-31 | $33,605 | 220 | Shares | Sole | 2026-04-20 | |
| 2025-12-31 | $30,331 | 220 | Shares | Sole | 2026-01-21 | |
| 2025-09-30 | $28,212 | 220 | Shares | Sole | 2025-10-24 | |
| 2025-06-30 | $26,622 | 220 | Shares | Sole | 2025-07-28 | |
| 2025-03-31 | $24,525 | 220 | Shares | Sole | 2025-04-07 | |
| No filing history on record for this holder in this stock. | ||||||